Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar

You may also be interested in...



China Broadens Scope Of Counterfeit Drugs For Criminal Prosecution, But Definition Still Murky

SHANGHAI - China recently broadened its criminal definition of counterfeit drugs to include all counterfeits, not just those that cause damage to human health. The revised Criminal Law opens more manufacturers of counterfeit drugs to criminal prosecution and makes prison terms mandatory for guilty parties

China Broadens Scope Of Counterfeit Drugs For Criminal Prosecution, But Definition Still Murky

SHANGHAI - China recently broadened its criminal definition of counterfeit drugs to include all counterfeits, not just those that cause damage to human health. The revised Criminal Law opens more manufacturers of counterfeit drugs to criminal prosecution and makes prison terms mandatory for guilty parties

China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce

BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China

Related Content

UsernamePublicRestriction

Register

SC071624

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel